FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1993122793> ?p ?o ?g. }

• W1993122793 endingPage "408" @default.
• W1993122793 startingPage "402" @default.
• W1993122793 abstract "Kaposi's sarcoma (KS) is a disease of multifocal vascular proliferation that requires infection with KS herpes virus (KSHV/HHV-8). Activation of the c-kit and platelet-derived growth factor (PDGF) receptors by autocrine/paracrine mechanisms follows endothelial cell KSHV infection. In a pilot study, imatinib, a c-kit/PDGF-receptor inhibitor, induced partial regression of AIDS-associated KS (AIDS-KS) in five of 10 patients.This multicenter phase II study was designed to estimate the response rate to imatinib in AIDS-KS. Secondary objectives included investigation of predictors of response and imatinib pharmacokinetics in patients on antiretrovirals. Patients received imatinib 400 mg/day by mouth for up to 12 months with dose escalation up to 600 mg/day at 3 months if their disease was stable.Thirty patients were treated at 12 AIDS Malignancy Consortium sites. Ten patients (33.3%) achieved partial response, six (20%) had stable disease, and seven (23.3%) exhibited KS progression. Nine patients completed 52 weeks of imatinib therapy. The median treatment duration was 22.5 weeks. Only five patients (16.7%) discontinued therapy owing to adverse events. Antiretroviral regimens did not significantly alter imatinib metabolism. Activating mutations in PDGF-R and c-kit were not found at baseline or at disease progression. We found no correlation with response with changes in any of the candidate cytokines.Imatinib has activity in AIDS-KS. Pharmacokinetic interactions with antiretroviral drugs did not correlate with toxicity. Thirty percent of patients showed long-term clinical benefit and remained on imatinib for the entire year. These results suggest imatinib is well tolerated and may be an alternative therapy for some patients with AIDS-KS." @default.
• W1993122793 created "2016-06-24" @default.
• W1993122793 creator A5014543424 @default.
• W1993122793 creator A5015341987 @default.
• W1993122793 creator A5019377044 @default.
• W1993122793 creator A5032508652 @default.
• W1993122793 creator A5038070558 @default.
• W1993122793 creator A5042621368 @default.
• W1993122793 creator A5047266965 @default.
• W1993122793 creator A5050919683 @default.
• W1993122793 creator A5056409417 @default.
• W1993122793 creator A5063693935 @default.
• W1993122793 creator A5063761389 @default.
• W1993122793 date "2014-02-10" @default.
• W1993122793 modified "2023-10-18" @default.
• W1993122793 title "Phase II Trial of Imatinib in AIDS-Associated Kaposi's Sarcoma: AIDS Malignancy Consortium Protocol 042" @default.
• W1993122793 cites W1968258480 @default.
• W1993122793 cites W2015015957 @default.
• W1993122793 cites W2015551422 @default.
• W1993122793 cites W2017210417 @default.
• W1993122793 cites W2021913096 @default.
• W1993122793 cites W2029409133 @default.
• W1993122793 cites W2034407706 @default.
• W1993122793 cites W2036830225 @default.
• W1993122793 cites W2049070399 @default.
• W1993122793 cites W2055515709 @default.
• W1993122793 cites W2074770401 @default.
• W1993122793 cites W2077002902 @default.
• W1993122793 cites W2077177885 @default.
• W1993122793 cites W2085632626 @default.
• W1993122793 cites W2096441602 @default.
• W1993122793 cites W2101818437 @default.
• W1993122793 cites W2114627676 @default.
• W1993122793 cites W2119131749 @default.
• W1993122793 cites W2121404525 @default.
• W1993122793 cites W2171722798 @default.
• W1993122793 cites W4235221876 @default.
• W1993122793 doi "https://doi.org/10.1200/jco.2012.48.6365" @default.
• W1993122793 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3912327" @default.
• W1993122793 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24378417" @default.
• W1993122793 hasPublicationYear "2014" @default.
• W1993122793 type Work @default.
• W1993122793 sameAs 1993122793 @default.
• W1993122793 citedByCount "87" @default.
• W1993122793 countsByYear W19931227932014 @default.
• W1993122793 countsByYear W19931227932015 @default.
• W1993122793 countsByYear W19931227932016 @default.
• W1993122793 countsByYear W19931227932017 @default.
• W1993122793 countsByYear W19931227932018 @default.
• W1993122793 countsByYear W19931227932019 @default.
• W1993122793 countsByYear W19931227932020 @default.
• W1993122793 countsByYear W19931227932021 @default.
• W1993122793 countsByYear W19931227932022 @default.
• W1993122793 countsByYear W19931227932023 @default.
• W1993122793 crossrefType "journal-article" @default.
• W1993122793 hasAuthorship W1993122793A5014543424 @default.
• W1993122793 hasAuthorship W1993122793A5015341987 @default.
• W1993122793 hasAuthorship W1993122793A5019377044 @default.
• W1993122793 hasAuthorship W1993122793A5032508652 @default.
• W1993122793 hasAuthorship W1993122793A5038070558 @default.
• W1993122793 hasAuthorship W1993122793A5042621368 @default.
• W1993122793 hasAuthorship W1993122793A5047266965 @default.
• W1993122793 hasAuthorship W1993122793A5050919683 @default.
• W1993122793 hasAuthorship W1993122793A5056409417 @default.
• W1993122793 hasAuthorship W1993122793A5063693935 @default.
• W1993122793 hasAuthorship W1993122793A5063761389 @default.
• W1993122793 hasBestOaLocation W19931227931 @default.
• W1993122793 hasConcept C126322002 @default.
• W1993122793 hasConcept C142724271 @default.
• W1993122793 hasConcept C143998085 @default.
• W1993122793 hasConcept C170493617 @default.
• W1993122793 hasConcept C180361614 @default.
• W1993122793 hasConcept C203014093 @default.
• W1993122793 hasConcept C2775960820 @default.
• W1993122793 hasConcept C2777583451 @default.
• W1993122793 hasConcept C2778256501 @default.
• W1993122793 hasConcept C2778729363 @default.
• W1993122793 hasConcept C2779399171 @default.
• W1993122793 hasConcept C71924100 @default.
• W1993122793 hasConcept C90924648 @default.
• W1993122793 hasConceptScore W1993122793C126322002 @default.
• W1993122793 hasConceptScore W1993122793C142724271 @default.
• W1993122793 hasConceptScore W1993122793C143998085 @default.
• W1993122793 hasConceptScore W1993122793C170493617 @default.
• W1993122793 hasConceptScore W1993122793C180361614 @default.
• W1993122793 hasConceptScore W1993122793C203014093 @default.
• W1993122793 hasConceptScore W1993122793C2775960820 @default.
• W1993122793 hasConceptScore W1993122793C2777583451 @default.
• W1993122793 hasConceptScore W1993122793C2778256501 @default.
• W1993122793 hasConceptScore W1993122793C2778729363 @default.
• W1993122793 hasConceptScore W1993122793C2779399171 @default.
• W1993122793 hasConceptScore W1993122793C71924100 @default.
• W1993122793 hasConceptScore W1993122793C90924648 @default.
• W1993122793 hasIssue "5" @default.
• W1993122793 hasLocation W19931227931 @default.
• W1993122793 hasLocation W19931227932 @default.
• W1993122793 hasLocation W19931227933 @default.
• W1993122793 hasLocation W19931227934 @default.

• next